Equine Herpesvirus 1 (EHV-1) PCR Fluxergy Assay*
A simple and cost-effective method to detect the gB/gD gene from an equine sample
Fast and accurate detection of gB/gD gene with minimal hands-on time per sample.
- Reduce long lab wait times
- Build on-site laboratory to facilitate better care
- Simple workflow with on-site training
*This Fluxergy product has not been cleared or approved by the USDA for veterinary diagnostic use, and is limited to use as individual laboratory components by experienced professional users in developing their own laboratory tests for research or animal use.
See our Specifications Below
~3 min from reagent thaw, No extraction required
gB and gD
(10.31 inches x 5.16 inches x 10.16 inches)
A veterinary tool for every Equine facility
On-site testing allows for you to initially prevent spread and react when outbreaks occur:
- Facilities and Barns
- Clinics & Referral Hospitals
- Ambulatory Practices
- Veterinary Teaching Hospitals
- Shows
- Racetracks
FAQs
In recent years, EHV-1 outbreaks at local and FEI shows have had drastic consequences, including numerous horses lost, dozens of show cancellations, and strict quarantines. Because some sectors of the equine community compete throughout the season, multiple shows, barns, and geographic regions can be at risk within a few days.
Yes, EHV-1 has been identified on wood shavings, leather, and other supplies for at least 48 hours, even on items stored outside or in cool temperatures.These findings emphasize the need for increased biosecurity, particularly within high-volume equine-related facilities.
Multiple outbreaks have occurred due to the arrival or return of horses, including clinically healthy horses. Incorporating EHV-1 monitoring–especially for horses traveling from high-risk areas or events–better protects local and international equine populations.
Equine Herpesvirus 1 (EHV-1) is a common and burdensome DNA virus in horse populations globally. It is highly contagious and spreads through direct horse-to-horse contact or indirect contact e.g. contaminated hands, equipment. Moreover, the neurologic form of the disease is particularly troublesome due to associated degrees of paralysis and is seen in approximately 10% of infected horses.
Current diagnostic testing requires use of PCR for specific diagnosis as clinical signs of EHV-1 mimic that of other respiratory pathogens and neurological diseases.
Due to the different presentations of EHV-1, correct and timely testing helps improve biosecurity.
Still have questions?
Testimonials
"I have conducted research on the Fluxergy system for the past 3 years. Having the capability to have a patient-side, reliable, sensitive, and cost-effective molecular detection instrument can be a tremendous improvement in the diagnostic field. Fluxergy’s advanced technology can potentially be used on clinical and subclinical horses in order to allow for proper treatment and timely biosecurity. Fluxergy’s novel platform can turn a 1 to 3-day turnaround time into a 1-hour processing time."
Dr. Nicola Pusterla
UC Davis School of Veterinary Medicine
"It is great to have the Fluxergy PCR platform on-site. The quick turnaround time makes a huge difference for our clients and patients, and we anticipate that we will be able to use this technology in many different aspects of equine veterinary medicine. It has the potential to rapidly confirm viral cases in densely populated equine areas, which will significantly improve disease management strategies. Overall, we are extremely pleased with this technology."
Peter Heidmann
Head of Internal Medicine Palm Beach Equine
“I learned of Fluxergy’s technology when I was at Boehringer Ingelheim, and I was impressed about the opportunity for this point-of-care testing platform. I am happy to be involved on Fluxergy’s advisory board where I can bring my 20+ years of animal health and R&D experience. One of the big advantages of Fluxergy’s technology is that it is very easy to use. When veterinarians see horses with high fevers, its important that they can understand quickly what is going on.”
Dr. Randolph Seidler, VMD, MBA
Boehringer Ingelheim